ROVI achieves second place in a worldwide sustainability rating

Laboratorios Farmacéuticos ROVI, S.A. achieved the second best ESG rating out of 432 companies assessed in the pharmaceutical industry category


ROVI’s ESG aspects have been evaluated by Sustainalytics, a Global Leader in ESG & Corporate Governance, obtaining an “ESG Risk Rating 2020” of 18.4, which places the company at low risk (between 10 and 20). This rating is 3.4 points higher than the previous year’s rating (21.8), when the company reached a medium risk position (between 20 and 30 points).

ROVI attains the second position out of 432 companies in the sub-industry “pharmaceuticals” and 17th out of a total of 896 companies in the “pharmaceutical industry”, which includes biotech, pharmaceutical and laboratory equipment companies.

No votes yet
 
Related
  Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
  Madrid, 8 May 2025.- Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 7 May 2025, the Technological Development...
4 min
08/05/2025